LT3201196T - Sulieti pentaciklinio imidazolo dariniai - Google Patents

Sulieti pentaciklinio imidazolo dariniai

Info

Publication number: LT3201196T
Authority: LT; Lithuania
Prior art keywords: imidazole derivatives; fused pentacyclic; pentacyclic imidazole; fused; derivatives
Prior art date: 2014-10-03

Application number

LTEPPCT/EP2015/072868T

Other languages

English (en)

Inventor

Teresa DE HARO GARCIA

Michael Deligny

Jag Paul Heer

Joanna Rachel Quincey

Mengyang XUAN

Zhaoning Zhu

Daniel Christopher Brookings

Mark Daniel Calmiano

Yves EVRARD

Martin Clive Hutchings

James Andrew Johnson

Sophie JADOT

Jean KEYAERTS

Malcolm Mac Coss

Matthew Duncan Selby

Michael Alan SHAW

Dominique Louis Léon SWINNEN

Laurent Schio

Yann Foricher

Bruno Filoche-Romme

Original Assignee

UCB Biopharma SRL

Sanofi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-03

Filing date

2015-10-02

Publication date

2021-09-27

2015-10-02 Application filed by UCB Biopharma SRL, Sanofi filed Critical UCB Biopharma SRL

2021-09-27 Publication of LT3201196T publication Critical patent/LT3201196T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

LTEPPCT/EP2015/072868T 2014-10-03 2015-10-02 Sulieti pentaciklinio imidazolo dariniai LT3201196T (lt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP14290299		2014-10-03
EP15162641		2015-04-07
EP15171036		2015-06-08
PCT/EP2015/072868 WO2016050975A1 (en)	2014-10-03	2015-10-02	Fused pentacyclic imidazole derivatives

Publications (1)

Publication Number	Publication Date
LT3201196T true LT3201196T (lt)	2021-09-27

Family

ID=54238452

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/EP2015/072868T LT3201196T (lt)	2014-10-03	2015-10-02	Sulieti pentaciklinio imidazolo dariniai

Country Status (36)

Country	Link
US (3)	US10202405B2 (lt)
EP (1)	EP3201196B1 (lt)
JP (1)	JP6629847B2 (lt)
KR (1)	KR102442235B1 (lt)
CN (1)	CN107108672B (lt)
AP (1)	AP2017009809A0 (lt)
AU (1)	AU2015326798B2 (lt)
BR (1)	BR112017006669B1 (lt)
CA (1)	CA2962826C (lt)
CL (1)	CL2017000787A1 (lt)
CO (1)	CO2017003331A2 (lt)
CR (1)	CR20170167A (lt)
DK (1)	DK3201196T3 (lt)
EA (1)	EA032839B1 (lt)
EC (1)	ECSP17027306A (lt)
ES (1)	ES2885432T3 (lt)
GT (1)	GT201700044A (lt)
HR (1)	HRP20211605T1 (lt)
HU (1)	HUE056133T2 (lt)
IL (1)	IL251147B (lt)
LT (1)	LT3201196T (lt)
MA (1)	MA40770B1 (lt)
MX (1)	MX2017004201A (lt)
MY (1)	MY181019A (lt)
PE (1)	PE20170693A1 (lt)
PH (1)	PH12017500414B1 (lt)
PL (1)	PL3201196T3 (lt)
RS (1)	RS62423B1 (lt)
SG (1)	SG11201701796XA (lt)
SI (1)	SI3201196T1 (lt)
TN (1)	TN2017000083A1 (lt)
TW (1)	TWI719949B (lt)
UA (1)	UA120764C2 (lt)
UY (1)	UY36341A (lt)
WO (1)	WO2016050975A1 (lt)
ZA (1)	ZA201701946B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI719949B (zh) *	2014-10-03	2021-03-01	比利時商Ｕｃｂ生物製藥公司	稠合五環咪唑衍生物
AR104291A1 (es)	2015-04-17	2017-07-12	Abbvie Inc	Moduladores tricíclicos de la señalización por tnf
UY36629A (es)	2015-04-17	2016-11-30	Abbvie Inc	Indazolonas como moduladores de la señalización de tnf
UY36628A (es)	2015-04-17	2016-11-30	Abbvie Inc	Indazolonas como moduladores de la señalización de tnf
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
CN109219609B (zh)	2016-04-01	2022-02-01	Ucb生物制药私人有限公司	作为tnf活性调节剂的稠合六环咪唑衍生物
US10654861B2 (en)	2016-04-01	2020-05-19	UCB Biopharma SRL	Fused pentacyclic imidazole derivatives as modulators of TNF activity
WO2017167996A1 (en)	2016-04-01	2017-10-05	Ucb Biopharma Sprl	Fused pentacyclic imidazole derivatives as modulators of tnf activity
EA201892153A1 (ru)	2016-04-01	2019-04-30	Юсб Байофарма Спрл	Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
GB201620948D0 (en)	2016-12-09	2017-01-25	Ucb Biopharma Sprl	Therapeutic agents
GB201621907D0 (en)	2016-12-21	2017-02-01	Ucb Biopharma Sprl And Sanofi	Antibody epitope
CN110461842A (zh) *	2017-03-15	2019-11-15	Ucb生物制药私人有限公司	作为tnf活性调节剂的稠合五环咪唑衍生物
SI3615534T1 (sl) *	2017-04-25	2022-01-31	UCB Biopharma SRL	Derivati zlitega pentacikličnega imidazola kot modulatorji delovanja TNF
JP7429694B2 (ja) *	2018-10-24	2024-02-08	ユーシービーバイオファルマエスアールエル	Ｔｎｆ活性のモジュレータとしての縮合五環式イミダゾール誘導体
CN113683505A (zh) *	2021-09-29	2021-11-23	厦门大华本安化工安全研究院有限公司	一种含氧代环丁基的羧酸酯类化合物的制备方法
US20240247014A1 (en) *	2022-11-23	2024-07-25	Forward Therapeutics, Inc.	Modulators of tnf-alpha activity
WO2024129763A1 (en) *	2022-12-13	2024-06-20	Forward Therapeutics, Inc.	MODULATORS OF TNF-α ACTIVITY
WO2024148191A1 (en) *	2023-01-05	2024-07-11	Forward Therapeutics, Inc.	MODULATORS OF TNF-α ACTIVITY
WO2024223740A1 (en)	2023-04-26	2024-10-31	Sanofi	Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0449649A3 (en)	1990-03-30	1992-09-02	Arizona Board Of Regents, Arizona State University	Antineoplastic quinones and methods of using same
FR2832711B1 (fr)	2001-11-26	2004-01-30	Warner Lambert Co	Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
BRPI0408477A (pt)	2003-03-10	2006-04-04	Pfizer	compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
DE102008030206A1 (de)	2008-06-25	2009-12-31	Bayer Schering Pharma Aktiengesellschaft	3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
TW201242953A (en)	2011-03-25	2012-11-01	Bristol Myers Squibb Co	Imidazole prodrug LXR modulators
KR101941420B1 (ko)	2011-06-20	2019-01-23	스페로 트리넴, 인코포레이티드	자이라제 및 토포이소머라제 억제제의 인산에스테르
CN104428293B (zh) *	2012-06-11	2018-06-08	Ucb生物制药私人有限公司	调节TNFα的苯并咪唑类
CN104619709B (zh) *	2012-07-13	2016-11-09	Ucb生物制药私人有限公司	作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) *	2012-07-13	2012-08-29	Ucb Pharma Sa	Therapeutic agents
US9266883B2 (en)	2013-10-25	2016-02-23	Novartis Ag	Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
GB201321729D0 (en)	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
GB201321728D0 (en)	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
SI3925607T1 (sl)	2014-04-15	2023-10-30	Vertex Pharmaceuticals Incorporated	Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi
TWI719949B (zh) *	2014-10-03	2021-03-01	比利時商Ｕｃｂ生物製藥公司	稠合五環咪唑衍生物

2015
- 2015-10-02 TW TW104132631A patent/TWI719949B/zh active
- 2015-10-02 MA MA40770A patent/MA40770B1/fr unknown
- 2015-10-02 MX MX2017004201A patent/MX2017004201A/es unknown
- 2015-10-02 EP EP15771976.6A patent/EP3201196B1/en active Active
- 2015-10-02 CN CN201580053711.8A patent/CN107108672B/zh active Active
- 2015-10-02 HU HUE15771976A patent/HUE056133T2/hu unknown
- 2015-10-02 EA EA201790734A patent/EA032839B1/ru not_active IP Right Cessation
- 2015-10-02 PL PL15771976T patent/PL3201196T3/pl unknown
- 2015-10-02 UY UY0001036341A patent/UY36341A/es not_active Application Discontinuation
- 2015-10-02 ES ES15771976T patent/ES2885432T3/es active Active
- 2015-10-02 CA CA2962826A patent/CA2962826C/en active Active
- 2015-10-02 LT LTEPPCT/EP2015/072868T patent/LT3201196T/lt unknown
- 2015-10-02 SI SI201531711T patent/SI3201196T1/sl unknown
- 2015-10-02 HR HRP20211605TT patent/HRP20211605T1/hr unknown
- 2015-10-02 CR CR20170167A patent/CR20170167A/es unknown
- 2015-10-02 MY MYPI2017701132A patent/MY181019A/en unknown
- 2015-10-02 US US15/513,357 patent/US10202405B2/en active Active
- 2015-10-02 PE PE2017000544A patent/PE20170693A1/es unknown
- 2015-10-02 JP JP2017518131A patent/JP6629847B2/ja active Active
- 2015-10-02 KR KR1020177011958A patent/KR102442235B1/ko active IP Right Grant
- 2015-10-02 AP AP2017009809A patent/AP2017009809A0/en unknown
- 2015-10-02 RS RS20211235A patent/RS62423B1/sr unknown
- 2015-10-02 DK DK15771976.6T patent/DK3201196T3/da active
- 2015-10-02 UA UAA201702002A patent/UA120764C2/uk unknown
- 2015-10-02 SG SG11201701796XA patent/SG11201701796XA/en unknown
- 2015-10-02 TN TN2017000083A patent/TN2017000083A1/en unknown
- 2015-10-02 WO PCT/EP2015/072868 patent/WO2016050975A1/en active Application Filing
- 2015-10-02 BR BR112017006669-6A patent/BR112017006669B1/pt active IP Right Grant
- 2015-10-02 AU AU2015326798A patent/AU2015326798B2/en active Active
2017
- 2017-03-06 PH PH12017500414A patent/PH12017500414B1/en unknown
- 2017-03-07 GT GT201700044A patent/GT201700044A/es unknown
- 2017-03-14 IL IL251147A patent/IL251147B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01946A patent/ZA201701946B/en unknown
- 2017-03-31 CL CL2017000787A patent/CL2017000787A1/es unknown
- 2017-04-06 CO CONC2017/0003331A patent/CO2017003331A2/es unknown
- 2017-05-03 EC ECIEPI201727306A patent/ECSP17027306A/es unknown
2018
- 2018-12-14 US US16/220,847 patent/US10906919B2/en active Active
2020
- 2020-11-24 US US17/102,790 patent/US11912721B2/en active Active

Also Published As

Publication number	Publication date
TN2017000083A1 (en)	2018-07-04
UY36341A (es)	2016-04-29
MX2017004201A (es)	2017-05-30
US20190367535A1 (en)	2019-12-05
UA120764C2 (uk)	2020-02-10
US11912721B2 (en)	2024-02-27
SI3201196T1 (sl)	2021-12-31
US20170305932A1 (en)	2017-10-26
US10202405B2 (en)	2019-02-12
KR20170068503A (ko)	2017-06-19
CA2962826C (en)	2023-08-08
TWI719949B (zh)	2021-03-01
CL2017000787A1 (es)	2017-11-24
MA40770B1 (fr)	2021-11-30
PE20170693A1 (es)	2017-06-13
ZA201701946B (en)	2018-07-25
BR112017006669B1 (pt)	2023-04-18
IL251147A0 (en)	2017-04-30
ES2885432T3 (es)	2021-12-13
EA032839B1 (ru)	2019-07-31
HRP20211605T1 (hr)	2022-01-21
RS62423B1 (sr)	2021-10-29
EP3201196A1 (en)	2017-08-09
HUE056133T2 (hu)	2022-01-28
SG11201701796XA (en)	2017-04-27
KR102442235B1 (ko)	2022-09-08
MY181019A (en)	2020-12-16
BR112017006669A2 (pt)	2017-12-26
NZ730256A (en)	2021-05-28
JP6629847B2 (ja)	2020-01-15
CO2017003331A2 (es)	2017-09-29
EP3201196B1 (en)	2021-07-28
CN107108672A (zh)	2017-08-29
MA40770A (fr)	2021-03-24
US20210155637A1 (en)	2021-05-27
WO2016050975A1 (en)	2016-04-07
AP2017009809A0 (en)	2017-03-31
US10906919B2 (en)	2021-02-02
JP2017531648A (ja)	2017-10-26
PL3201196T3 (pl)	2022-01-03
ECSP17027306A (es)	2017-05-31
AU2015326798B2 (en)	2020-01-02
AU2015326798A1 (en)	2017-04-06
PH12017500414A1 (en)	2017-07-17
CA2962826A1 (en)	2016-04-07
PH12017500414B1 (en)	2017-07-17
GT201700044A (es)	2019-09-09
IL251147B (en)	2020-05-31
CN107108672B (zh)	2019-11-08
CR20170167A (es)	2017-08-10
TW201629067A (zh)	2016-08-16
DK3201196T3 (da)	2021-09-06
EA201790734A1 (ru)	2017-09-29

Publication	Publication Date	Title
ZA201701946B (en)	2018-07-25	Fused pentacyclic imidazole derivatives
SG11201609205WA (en)	2016-12-29	Heterocyclyl-butanamide derivatives
HUE050450T2 (hu)	2020-12-28	Fluoralkil-fluorén-származékok
EP3140315C0 (en)	2024-07-24	NEW CATH2 DERIVATIVES
HRP20182016T1 (hr)	2019-01-25	Derivati etinila
EP3099672A4 (en)	2017-09-20	Fused imidazole compounds
IL248773A0 (en)	2017-01-31	History of naphthyridinedione
HK1245269A1 (zh)	2018-08-24	咪唑衍生物
PL3418273T3 (pl)	2022-08-01	Pochodne flawaglin
IL248629B (en)	2019-07-31	Substances containing diheteroaryl conjugated to cycloalkyl and their uses
GB201414116D0 (en)	2014-09-24	Benzodiazepine derivatives
PL3119744T3 (pl)	2019-07-31	Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
IL248900A0 (en)	2017-01-31	pyrazine derivatives
GB201416351D0 (en)	2014-10-29	Heterocyclic derivatives
PL3228616T3 (pl)	2020-03-31	Pochodne pirydyny
PT3201196T (pt)	2021-09-02	Derivados de imidazol pentacíclicos fusionados